Burlington, North Carolina, USA, November 17, 2026
Labcorp has announced a strategic collaboration with Grupo Fleury, one of Brazil’s leading healthcare and diagnostic groups, to expand its clinical trial operations in Brazil. The collaboration will introduce dedicated local clinical trial kit assembly services, followed by the planned development of laboratory operations in the country. The expansion is designed to bring clinical research support closer to investigators, research sites and patients while helping pharmaceutical and biotechnology sponsors manage multinational clinical studies more efficiently. By combining Labcorp’s global clinical trial capabilities with Grupo Fleury’s established laboratory infrastructure and local scientific expertise, the partnership aims to strengthen Brazil’s role in international clinical research. The initiative will also extend Labcorp’s clinical trial support network to five continents, broadening its ability to serve sponsors conducting studies across multiple regions.
Labcorp and Grupo Fleury Strengthen Brazil’s Clinical Research Infrastructure
The collaboration brings together Labcorp’s global experience in central laboratory services and clinical trial support with Grupo Fleury’s extensive healthcare and diagnostic network in Brazil. The partnership is intended to establish local operational capabilities that can support clinical research sponsors throughout the country. Brazil is an important destination for clinical trials because of its diverse patient population, experienced investigators and growing scientific capabilities. These characteristics can help sponsors recruit participants and conduct research across different patient populations and healthcare settings. Through the collaboration, Labcorp plans to provide services locally while maintaining the scientific expertise, operational consistency and quality standards applied across its international network. Brian Caveney, M.D., president of biopharma laboratory services and chief medical and scientific officer at Labcorp, highlighted the importance of combining global expertise with local insight as clinical trials increasingly involve multiple countries. Grupo Fleury also emphasised that its understanding of Brazil’s healthcare and research environment, together with Labcorp’s international capabilities, could help improve trial efficiency and expand research opportunities.
Local Kit Assembly Planned for Early 2027
A key initial component of the expansion will be the establishment of dedicated clinical trial kit assembly operations in Brazil, which are expected to begin in early 2027. Clinical trial kits are essential to research operations because they support the collection, handling and processing of samples required by study protocols. Establishing local assembly capabilities is expected to help reduce the time required to deliver kits to research sites and decrease dependence on international shipping. Faster and more reliable kit availability can support site readiness, simplify logistics and help sponsors coordinate activities across geographically dispersed clinical trial locations. Labcorp expects these improvements to contribute to more efficient study execution and closer operational support for investigators and patients. The planned services will be supported by Labcorp’s established global systems and processes, with the objective of maintaining consistent operational and quality requirements across multinational studies. The company expects the local infrastructure to help sponsors manage trial-related logistics while benefiting from Grupo Fleury’s established presence in Brazil.
Future Laboratory Operations to Extend Global Trial Support
Beyond kit assembly, the collaboration includes plans for clinical trial laboratory operations in Brazil, which remain under development and are expected to launch by the end of 2027. Once established, these operations are intended to provide additional local support for clinical research programmes while connecting with Labcorp’s existing central laboratory network across North America, Europe, Asia and Africa. The Brazil expansion will extend the company’s clinical trial support capabilities across five continents. Both the planned kit assembly and laboratory operations are expected to use Labcorp’s global systems, processes and quality standards, supporting data consistency and operational alignment in multinational clinical trials. The company expects the expanded presence to shorten kit delivery timelines, reduce international shipping requirements and improve overall efficiency for clinical trial sponsors. These benefits are particularly relevant to studies that depend on coordinated sample collection and laboratory support across several countries.
The announcement reflects the continuing development of Brazil as a location for global clinical research and highlights the importance of local infrastructure in supporting complex clinical programmes. For pharmaceutical and biotechnology companies, access to regional laboratory capabilities and reliable trial logistics can help simplify study management and support collaboration with research sites. The partnership between Labcorp and Grupo Fleury represents a planned investment in clinical research infrastructure rather than an immediate launch of fully operational laboratory services. Kit assembly is expected to begin in early 2027, while laboratory operations are targeted for the end of that year. The expansion could strengthen clinical trial support for sponsors operating in Brazil and contribute to the country’s growing participation in international drug development research.
Source: Labcorp press release



